Clinical Chemistry
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 QUICK SEARCH:   [advanced]


     


Clinical Chemistry 46: 1610-1618, 2000;
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Web of Science (30)
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Nurmikko, P.
Right arrow Articles by Pettersson, K.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Nurmikko, P.
Right arrow Articles by Pettersson, K.
Related Collections
Right arrow Proteomics and Protein Markers
(Clinical Chemistry. 2000;46:1610-1618.)
© 2000 American Association for Clinical Chemistry, Inc.


Articles

Production and Characterization of Novel Anti-Prostate-specific Antigen (PSA) Monoclonal Antibodies That Do Not Detect Internally Cleaved Lys145-Lys146 Inactive PSA

Pauliina Nurmikko1,a, Ville Väisänen1, Timo Piironen1, Sari Lindgren1, Hans Lilja2 and Kim Pettersson1

1 Department of Biotechnology, University of Turku, Tykistökatu 6A 6th Floor, FIN-20520 Turku, Finland.

2 Department of Clinical Chemistry, Lund University, University Hospital, S-20502 Malmö, Sweden.
a Author for correspondence. Fax 358-2-3338050; e-mail pauliina.nurmikko{at}utu.fi

Background: The nature of free, uncomplexed prostate-specific antigen (PSA) in the circulation is still unknown. In this study, we developed novel anti-PSA antibodies using PSA produced by a metastasized cancer cell line, LNCaP, as an immunogen.

Methods: Hybridoma cell lines were screened with different methods that aimed at finding antibodies specific for the forms of free PSA produced by LNCaP cell line. Obtained antibodies were further studied for their characteristics related to previously characterized monoclonal antibodies.

Results: Numerous anti-PSA antibodies were obtained, of which four represented unique epitopes previously unrecognized by us. One free-PSA-specific antibody was bound to PSA on two distinct epitopes, and one antibody was bound to the carboxyl-terminal peptide of PSA. Two antibodies were found to bind to the peptide sequence adjacent to the internal cleavage site Lys145-Lys146. These antibodies failed to recognize internally cleaved PSA at Lys145-Lys146. We could not find anti-proPSA antibodies despite the fact that LNCaP PSA contained more than one-half of the zymogen form of PSA.

Conclusions: We report, for the first time, novel anti-PSA antibodies that do not recognize internally cleaved PSA at Lys145-Lys146 and thus are specific for intact, unclipped PSA.




The following articles in journals at HighWire Press have cited this article:


Home page
Anticancer ResHome page
C. STEPHAN, H. RITTENHOUSE, H. CAMMANN, M. LEIN, M. SCHRADER, S. DEGER, K. MILLER, and K. JUNG
New Markers and Multivariate Models for Prostate Cancer Detection
Anticancer Res, July 1, 2009; 29(7): 2589 - 2600.
[Abstract] [Full Text] [PDF]


Home page
Clin. Chem.Home page
V. Vaisanen, S. Eriksson, K. K. Ivaska, H. Lilja, M. Nurmi, and K. Pettersson
Development of Sensitive Immunoassays for Free and Total Human Glandular Kallikrein 2
Clin. Chem., September 1, 2004; 50(9): 1607 - 1617.
[Abstract] [Full Text] [PDF]


Home page
Clin. Chem.Home page
A. Haese, V. Vaisanen, J. A. Finlay, K. Pettersson, H. G. Rittenhouse, A. W. Partin, D. J. Bruzek, L. J. Sokoll, H. Lilja, and D. W. Chan
Standardization of Two Immunoassays for Human Glandular Kallikrein 2
Clin. Chem., April 1, 2003; 49(4): 601 - 610.
[Abstract] [Full Text] [PDF]


Home page
Cancer Res.Home page
S. D. Mikolajczyk, K. M. Marker, L. S. Millar, A. Kumar, M. S. Saedi, J. K. Payne, C. L. Evans, C. L. Gasior, H. J. Linton, P. Carpenter, et al.
A Truncated Precursor Form of Prostate-specific Antigen Is a More Specific Serum Marker of Prostate Cancer
Cancer Res., September 1, 2001; 61(18): 6958 - 6963.
[Abstract] [Full Text] [PDF]


Home page
Clin. Chem.Home page
P. Nurmikko, K. Pettersson, T. Piironen, J. Hugosson, and H. Lilja
Discrimination of Prostate Cancer from Benign Disease by Plasma Measurement of Intact, Free Prostate-specific Antigen Lacking an Internal Cleavage Site at Lys145-Lys146
Clin. Chem., August 1, 2001; 47(8): 1415 - 1423.
[Abstract] [Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 2000 by the American Association for Clinical Chemistry.